Cann Group and IDT have finished packing Cann's first Australian medicinal cannabis product to be tested and commercially released within the next three months.
Cann Group Limited (ASX: CAN) has just announced that its first commercial medicinal cannabis product has now been packed by IDT Australia Limited (ASX: IDT) under cGMP conditions to be tested and released in the first three months of 2020.
The medicinal raw flower product has been packed into 10-gram bottles within IDT's licensed facilities with testing data scheduled to be accessible at the end of next month.
This means that patients will be able to access products from the Cann Group in the first few months of 2020 through the Special Access Scheme (SAS,) to be distributed by Symbion Health throughout Symbion's wide-reaching network of pharmacies.
Amidst launching its first commercial medicinal product in Australia, Cann Group will also make its product available for export by converting the raw flower into cGMP grade Active Pharmaceutical Ingredients (API) to be distributed overseas.
The company has already exported its Australian-grown, packaged medicinal cannabis product to Aurora Cannabis in Canada, which Aurora will use for research purposes. The company also mentions that this exportation to Aurora also represents an "important validation of export pathways ahead of future commercial supply."
Peter Crock, Cann Group's CEO stated that "IDT has demonstrated a clear capability to manufacture cGMP medicinal cannabis products. As Cann Group increases our cultivation and production capacity at the new Mildura facility, it is critical that we have the ability to efficiently convert that material into commercial formulations."
IDT's CEO, Dr. David Sparling has echoed similar sentiments, showing his enthusiasm towards the production and packaging of Cann Group's first medicinal product, as well as IDT's future in working with pharmaceutical-grade cannabis.
"IDT is creating a new chapter in its long history of secure and high containment specialty pharmaceutical product manufacture. The Company has the requisite licences in place; and equipment and processes necessary to convert large quantities of medicinal cannabis starting materials into a range of innovative cGMP pharmaceutical products."
To learn more about Cann Group, visit their company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!